Gromov S A, Kim K V
Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(9):18-21.
Therapeutic efficacy of three original valproates (convulex, depakine enteric and convulsofine) as well as direct cost of drugs for epilepsy treatment have been studied in 249 patients with long-term epilepsy with different types of epileptic seizures. The convulex efficacy was found to be lower than that of the other two drugs. Also, convulex reduces the frequency of seizures by 50-100% in 75% of the patients. During the convulex treatment of some types of seizures, remission was achieved in 81-90% of the patients. At the same time, the cost of treatment with convulex is 1.5 times lower comparing to that with depakine and is equal to that for convulsofine. The authors concluded the cost benefit of convulex treatment appeared to stimulate regional health departments and individual patients for wholesale and retail drug purchases.
在249例患有不同类型癫痫发作的长期癫痫患者中，研究了三种原研丙戊酸盐（抗癫灵、德巴金肠溶片和抗痫灵）的治疗效果以及癫痫治疗药物的直接成本。发现抗癫灵的疗效低于其他两种药物。此外，75%的患者使用抗癫灵后癫痫发作频率降低了50 - 100%。在使用抗癫灵治疗某些类型的癫痫发作时，81 - 90%的患者实现了缓解。同时，抗癫灵的治疗成本比德巴金低1.5倍，与抗痫灵相当。作者得出结论，抗癫灵治疗的成本效益似乎促使地区卫生部门和个体患者进行药品的批发和零售采购。
